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Cancer poses one of the greatest human health threats of our time. Fortunately, aside from a
few rare cases of cancer transmission in immune-suppressed organ transplant recipients [1] or
a small number of transmission events from mother to fetus [2], cancers are not spread from
human to human. However, transmissible cancers have been detected in vertebrate and inver-
tebrate animals, sometimes with devastating effects [3]. Four examples of transmissible cancers
are now known: 1) canine transmissible venereal tumor (CTVT) in dogs [4], 2) a tumor in a
laboratory population of Syrian hamsters that is no longer cultured [3], 3) infectious neoplasias
in at least four species of bivalve mollusks [5,6], and 4) two independently derived transmissi-
ble cancers (devil facial tumor disease [DFTD]) in Tasmanian devils [7–10] (Fig 1A and 1B).
The etiologic agents of CTVT [4], the bivalve cancers [5], and DFTD [7] are the transplants
(allografts) of the neoplastic cells themselves, but the etiologic agent is unknown for the ham-
ster tumor.
The effects of these transmissible cancers on their respective host populations vary. CTVT
is spread in dogs through sexual contact and is at least 11,000 years old, placing the timing of
its origin close to that of the domestication of dogs [11]. Although genomic analyses of the
tumor suggest evasion of multiple components of the dog immune system, dogs most com-
monly survive and often show evidence of spontaneous tumor regression within a year of ini-
tial diagnosis [11,12]. For the infectious bivalve neoplasias, which have existed for at least 40
years, population effects vary from enzootic infections with no noticeable effects on population
sizes to evidence of a catastrophic population decline [6,13]. In Tasmanian devils (Fig 1A), the
first infectious tumor discovered (DFT1; Fig 1B) has spread across approximately 95% of the
geographic range of Tasmanian devils since 1996 (Fig 1C). DFTD is almost always fatal (Fig
1B), with>90% declines in infected localities and an overall species-wide decline exceeding
80% [14–16]. Transmission dynamics appear consistent with frequency dependence, with
DFTD spread by biting during social interactions [15], resulting in predictions of extinction
from standard epidemiological models [14]. Despite these predictions, long-infected devil
populations persist at reduced densities, suggesting that individual-level variability in fecun-
dity and tumor growth rate in infected individuals are key for understanding epidemiological
dynamics [17]. Additionally, the origin of the second, independent lineage of DFTD (i.e.,
DFT2) [9,10] within 20 years of the discovery of DFT1 suggests that transmissible cancers may
be a recurring part of the Tasmanian devils’ evolutionary history, without causing extinction
[17].
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The origin of Tasmanian devil facial tumor disease
Based on a transcriptomic analysis of DFT1, the progenitor tumor likely originated from a
mutated Schwann cell (a type of peripheral nerve cell) in a female Tasmanian devil [8]. DFT2
is also likely to be of neuroectodermal origin, but DFT2 does not express periaxin (PRX), a
Schwann cell marker present in DFT1 [10]. Both DFT1 and DFT2 likely evolved from Tasma-
nian devils located in eastern Tasmania, with their genetic assignments consistent with their
geographic origins (in the NE and SE, respectively) [10]. The gross morphology and histology
of DFT2 are different from DFT1 [9,10]. For example, DFT1 is generally composed of pleo-
morphic round cells in bundles, whereas DFT2 is typically characterized by pleomorphic
sheets of cells [9]. Moreover, DFT2 karyotypes have a Y chromosome, indicating that this
tumor arose from a male devil and thus independently from DFT1 [9]. Although DFT1 and
DFT2 originated in the last 21 years, no evidence has been found for viral origin, and results
are inconsistent with tumor evolution coming from exposure to anthropogenic stressors, such
as increased UV light [10].
Although the specific mechanism of how DFT1 or DFT2 became transmissible is still
unknown, several lines of evidence suggest that chromosomal rearrangements, common to
cancers, were critical [8,18]. Devils normally have six pairs of autosomes and one pair of sex
chromosomes [7,19,20], but cytogenetic analyses show large-scale rearrangements in both
DFT1 and DFT2 (Fig 2). To date, few isolates of DFT2 have been karyotyped, but DFT1 has
abnormalities associated with Chromosomes 1, 3, 4, 5, 6, and the X chromosome [19–21].
DFT1 is characterized by a series of marker chromosomes, including double minutes, that
vary in size and number among different cytogenetic strains [10,21]. Notably, both tumors
show rearrangement of Chromosome 1 (referred to as Chromosome 2 in [10]; see Fig 2)
[20,21]. Some karyotypes of DFT1 show complete fragmentation of Chromosome 1, as well as
fusion with parts of the X chromosome and Chromosome 5, whereas DFT2 has an insertion of
one copy of Chromosome 6 in the pericentric region in Chromosome 1 (Fig 2). Comparisons
with wallaby and opossum genomes suggest that Chromosome 1 has been prone to rearrange-
ment among marsupials [20]; Chromosome 1 rearrangements are stable in DFT1, indicating
their possible importance for tumor transmissibility and fitness [19,20]. Common to cancers,
DFT1 and DFT2 may have arisen from a critical shortening of telomeres on different
Fig 1. A. Healthy adult Tasmanian devil. B. Adult Tasmanian devil infected with devil facial tumor disease. C. Map of Tasmania
showing initial site of disease emergence (red dot). Curved lines show the disease front demarcated by the year devil facial tumor disease
was detected in each area. Photo Credit: Alexandra Fraik.
https://doi.org/10.1371/journal.ppat.1007098.g001
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chromosomes that led to these abnormal karyotypes [see 10,19,20]. Telomeres are DNA–pro-
tein complexes that protect against chromosomal degradation during cell replication [22].
When telomeres become critically short, the p53 pathway typically induces apoptosis (terminal
cell cycle arrest), but evasion of this pathway is often associated with cancer progression [23].
Fig 2. Karyotypes of a normal female Tasmanian devil (top) with a representative karyotype of DFT1 (middle) and DFT2 (bottom). Karyotypes of the Tasmanian
devil and DFT1 follow [19]; this arrangement differs from [10] in respect to Chromosomes 1 and 2, in which the positions are reversed. Colors in rearranged/
fragmented chromosomes indicate the chromosome from which the material originated in the normal devil karyotype. M1–M5 indicate marker chromosomes
resulting from fragmentation of Chromosome 1 and fusion with Chromosomes 5 and 1 in DFT1. Asterisks indicate those chromosomes/markers that have been
observed to vary among karyotyped strains of DFT1. DFT2 originated from a male devil and thus possesses a Y chromosome. While one copy of Chromosome 6
has been inserted into the pericentric region of Chromosome 1, the limited available karyotypes of DFT2 thus far suggest it is otherwise relatively undifferentiated
from the normal devil karyotype. DFT, devil facial tumor.
https://doi.org/10.1371/journal.ppat.1007098.g002
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At least 64 chromosomal rearrangements map to genic regions in DFT1, including a gene
encoding a histone methyltransferase (EZH2) that is dysregulated in many cancers [10]. Addi-
tional translocations include a homolog of a tumor suppressor gene (NF2) and a deletion of a
tumor suppressor copy (LZTR1). Moreover, there is evidence of copy number increases of two
genes (ERBB3 and GALNT2) that are overexpressed in many cancers, including schwannomas
[18,20]. While early mutations in DFT1 and DFT2 have no overlap, both tumors notably had
hemizygous mutations that led to deletion of second copies of genes in the Hippo pathway (WWC
in DFT1 and MPDZ in DFT2, respectively), implicated in several human cancer histotypes, partic-
ularly Schwann cell cancers [10]. Although both tumors are largely diploid, DFT2 appears to have
a simpler structure and fewer rearrangements (23 versus 64) as compared to DFT1 [10].
Tasmanian devil facial tumor disease: Genomics of susceptibility
For an allograft to avoid rejection from a new host, it must circumvent recognition by major
histocompatibility complex (MHC) genes [24]. MHC Class I is generally responsible for tumor
recognition via identification of cell surface proteins expressed as “nonself” on cancer cells
[24]; transmissible cancer cells are indeed nonself, having originated in a different individual
[3,6]. Ubiquitous susceptibility of Tasmanian devils to DFTD has been hypothesized to result
from low devil genetic variability overall [25], likely due to at least two historical genetic bottle-
necks [25,26]. Compared to other mammals, devils have particularly low genetic variability in
the MHC Class I peptide-binding region implicated in tumor recognition [27]. However,
MHC diversity is not linked to variation in disease susceptibility among individuals [28], and
devils reject allografts in challenge experiments [29]. Instead, DFT1 appears to down-regulate
its own MHC expression, as well as MHC expression in the devil [30]. Epigenetic down-regu-
lation of MHC expression is common in human cancers [31], as well as being a salient feature
in CTVT [12,18]. In addition to MHC evasion, there are at least several other mechanisms that
underlie widespread transmissibility of DFTD yet to be discovered. Moreover, there is docu-
mented variation in tumor susceptibility among devils, including rare documented cases of
tumor regression and immune response, which are discussed below.
Tasmanian devil facial tumor disease: Evolution of devils
Despite widespread declines of Tasmanian devils and predictions of localized devil extinctions,
continued devil survival may result from evolution of DFTD resistance, which is supported by
multiple lines of genetic evidence. First, a genome scan showed large and concordant allele fre-
quency changes and increases in linkage disequilibrium across three populations pre- and
post-disease [32]. Strong support for rapid evolution (in as few as four generations) was dis-
covered in two small genomic regions containing seven candidate genes mapped to the devil
reference genome; five of these genes were associated with immune- and cancer-related func-
tions, including cell adhesion and p53 pathways [32]. Second, a genome-wide association
study showed strong evidence that a few large-effect single nucleotide polymorphisms (SNPs
or single base pair changes in DNA) explain a significant proportion of observed phenotypic
variation in survival following infection in females [33]. Genes of particular interest in close
proximity with these SNPs also include cell adhesion, tumor suppression, and p53 pathway
genes [33]. Taken together, these two studies suggest evolution resulting from a soft selective
sweep, whereby selection acted on standing genetic variation in a few, large-effect loci, as
opposed to on new mutations [33]. A third study showed that DFTD was capable of swamping
local adaptation to weaker abiotic forces, such as altitude [34]. That is, selection by the biotic
factor of disease tended to overwhelm selection by abiotic factors in the predisease environ-
ment [34].
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Recent field studies also suggest evolution of DFTD resistance. For the first time, spontane-
ous regression of tumors, a phenomenon rarely seen in human cancers without treatment, has
been documented in devils [35]. A comparative genomic study of devils with tumor regression
versus those that succumbed to the disease shows evidence that two devil candidate genes
(TLL1 and NBAS1) are involved in the regression process [35,36]. The two genes, plus a third
(PAX3, which is not significant after genome-wide correction), are involved in stimulating
angiogenesis in both normal growth and cancer metastases, perhaps increasing tumor vascu-
larization to enable lymphocyte penetration. Indeed, Pye and colleagues [36], in the first study
that demonstrates evidence of adaptive immune response to DFTD, show that one devil had
prominent lymphocyte infiltration in its tumor. The same study shows presence of serum anti-
bodies against DFTD cells in six of 52 devils tested, and that four of these six devils had histo-
ries of tumor regression [36].
Tasmanian devil facial tumor disease: Evolution of the tumors
Cytogenetic analyses currently recognize four karyotypes of DFT1 [21] and show that genomic
rearrangements are limited to particular cancer regions, suggesting at least some genomic sta-
bility [19,20]. When compared to the Tasmanian devil reference genome, two strains of DFT1
collected from SE and north central Tasmania, respectively, accumulated between 15,000 and
17,000 single-nucleotide substitutions between them [18]. Assuming they share a common
ancestor that emerged approximately 20 years ago, this mutation rate is higher than most
human cancers (approximately 5,000) but lower than lung cancer or melanomas [18]. Evi-
dence of within-host tumor variation is limited; of 20 devils with multiple tumors, only six
individuals had tumors that were genetically distinguishable. A comparison of the mitochon-
drial genomes of 104 DFT1 tumors from 69 devils across Tasmania showed limited among-
host genetic variability as well, with 21 somatic variants detected [18].
Overall, there appears to be variation in fitness across different DFT1 lineages. Evidence for
this comes from displacement of one tumor lineage by another in at least one area of Tasmania
[16] but coexistence of multiple lineages in other areas [18]. Currently, DFT2 is still limited in
its geographic distribution, and it is not yet known how fast the lineage is evolving, nor how its
fitness or effects on devil fitness compare with DFT1. However, early evidence suggests that
DFT2 primarily infects males (9/11 documented cases), possibly indicating relative differences
in susceptibility between males and females [10].
Conclusion
Transmissible cancers are indeed a frightening phenomenon, and the recent appearance of a
malignancy of tapeworm origin in an HIV-infected individual [37] shows that tumors derived
from nonhost DNA can emerge spontaneously in immune-suppressed humans. As a species,
the Tasmanian devil has perhaps suffered most extensively, with massive population declines
resulting from the emergence and spread DFTD. Fortunately, a combination of genomic and
immunological studies provide compelling evidence of devil evolutionary responses that
appear to be related to DFTD resistance or tolerance. Further, an in vitro drug screen showed
promise for possible oral treatment therapies; both DFT1 and DFT2 are highly sensitive to sev-
eral clinical compounds, and DFTs apparently show low tolerance to DNA damage [10]. The
development of numerous genomic data sets to study human cancers, DFTD, CTVT, and
soon likely the bivalve neoplasias provides extensive resources for the study of cancer trans-
missibility. Further research that uses comparative genomics and transcriptomics, such as the
recent comparison of DFT1 and DFT2 [10], will likely be fruitful for understanding the origin
and evolution of cancer transmissibility in general.
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